Biosimilar switch works for most patients in Real-World study
NCT ID NCT02998398
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested what happens when patients with rheumatoid arthritis, Crohn's disease, or eye inflammation switch from the original drug Remicade to its lower-cost biosimilar Inflectra. Over 260 adults who had been on Remicade for at least 4 months were switched. The main goal was to see how many stayed on Inflectra after three doses. Results help doctors understand if switching is a safe and effective option in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- biosimilar infliximab (Inflectra)
- What this could lead to
- If successful, this could show that switching to a biosimilar is safe and effective, potentially lowering treatment costs for patients with inflammatory diseases.
- What could go wrong
- This is a small, single-hospital study without a comparison group. Results may not apply to all patients, and some may experience disease flares or develop antibodies after switching.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Cochin
Paris, Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- AI reads scans to forecast Crohn's complications